<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lu P</submitter><funding>Startup Fund for Scientific Research, Fujian Medical University</funding><funding>Fujian Provincial Natural Science Foundation of China</funding><funding>the Joint Funds for the Innovation of Science and Technology, Fujian province</funding><funding>Fujian provincial health technology project</funding><pagination>348</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12923716</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Oxaliplatin (OXA) resistance poses a significant challenge to the efficacy of chemotherapy for advanced colorectal cancer (CRC). This study aimed to elucidate the role of OXA in regulating Cysteine-rich protein 61 (Cyr61) expression via the Hippo-Yes-associated protein (YAP) pathway in the context of chemotherapy-induced drug resistance.&lt;h4>Methods&lt;/h4>We used Cell Counting Kit-8 to detect cell viability and proliferation. Expression of Cyr61 was determined by quantitative real-time PCR, western blotting (WB) and Enzyme-linked immunosorbent assay in CRC cell lines. The mechanism of OXA in regulating Cyr61 expression was studied by WB and co-immunoprecipitation.&lt;h4>Results&lt;/h4>The results revealed that exposure to varying concentrations of OXA for 24 h induced increased m</pubmed_abstract><journal>Discover oncology</journal><pubmed_title>Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells.</pubmed_title><pmcid>PMC12923716</pmcid><funding_grant_id>2020Y9088</funding_grant_id><funding_grant_id>2021GGA015</funding_grant_id><funding_grant_id>2024J01596</funding_grant_id><funding_grant_id>2023QH1057</funding_grant_id><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Huang Z</pubmed_authors><pubmed_authors>Cao Y</pubmed_authors><pubmed_authors>Zheng C</pubmed_authors><pubmed_authors>Zhu X</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Lu P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells.</name><description>&lt;h4>Background&lt;/h4>Oxaliplatin (OXA) resistance poses a significant challenge to the efficacy of chemotherapy for advanced colorectal cancer (CRC). This study aimed to elucidate the role of OXA in regulating Cysteine-rich protein 61 (Cyr61) expression via the Hippo-Yes-associated protein (YAP) pathway in the context of chemotherapy-induced drug resistance.&lt;h4>Methods&lt;/h4>We used Cell Counting Kit-8 to detect cell viability and proliferation. Expression of Cyr61 was determined by quantitative real-time PCR, western blotting (WB) and Enzyme-linked immunosorbent assay in CRC cell lines. The mechanism of OXA in regulating Cyr61 expression was studied by WB and co-immunoprecipitation.&lt;h4>Results&lt;/h4>The results revealed that exposure to varying concentrations of OXA for 24 h induced increased m</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-09T11:49:24.452Z</modification><creation>2026-07-09T11:02:21.765Z</creation></dates><accession>S-EPMC12923716</accession><cross_references><pubmed>41606217</pubmed><doi>10.1007/s12672-026-04530-2</doi></cross_references></HashMap>